Compare · HZAC vs HZNP
HZAC vs HZNP
Side-by-side comparison of Horizon Acquisition Corporation (HZAC) and Horizon Therapeutics Public Limited Company (HZNP): market cap, price performance, sector, and recent activity on the wire.
Summary
- HZAC operates in Finance, while HZNP operates in Health Care - the two are in different parts of the market.
- HZNP is the larger of the two at $20.72B, about 25.3x HZAC ($818.0M).
- HZNP has more recent analyst coverage (14 ratings vs 4 for HZAC).
- Company
- Horizon Acquisition Corporation
- Horizon Therapeutics Public Limited Company
- Price
- $12.27+1.95%
- $116.30+0.03%
- Market cap
- $818.0M
- $20.72B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Business Services
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- 2011
- News (4w)
- 0
- 0
- Recent ratings
- 4
- 14
Horizon Acquisition Corporation
Horizon Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on pursuing opportunities in financial, technology and business services sectors. The company was formerly known as EAC Holdings Inc. Horizon Acquisition Corporation was incorporated in 2020 and is based in Greenwich, Connecticut.
Horizon Therapeutics Public Limited Company
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Latest HZAC
- SEC Form 15-12B filed by Horizon Acquisition Corporation
- SEC Form SC 13D/A filed by Horizon Acquisition Corporation (Amendment)
- SEC Form 4: Horizon Sponsor, Llc was granted 50,000 units of Class A ordinary shares and returned 15,550,000 units of Class A ordinary shares to the company
- SEC Form 25 filed by Horizon Acquisition Corporation
- Vivid Seats and Horizon Acquisition Corporation Announce Closing of Business Combination
- SEC Form 425 filed by Horizon Acquisition Corporation
- SEC Form 425 filed by Horizon Acquisition Corporation
- Horizon Acquisition Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Horizon Acquisition Corp. Shareholders Approve Business Combination with Vivid Seats Inc.
- SEC Form 425 filed by Horizon Acquisition Corporation
Latest HZNP
- Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting
- SEC Form 15-12G filed by Horizon Therapeutics Public Limited Company
- Watkins Thomas returned $20,550,600 worth of Ordinary Shares to the company (176,400 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Mahony Susan returned $2,172,842 worth of Ordinary Shares to the company (18,651 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Witz Pascale returned $5,353,292 worth of Ordinary Shares to the company (45,951 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Grey Michael G returned $11,346,168 worth of Ordinary Shares to the company (97,392 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Daniel William F returned $9,271,652 worth of Ordinary Shares to the company (79,585 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Himawan Jeff returned $10,371,762 worth of Ordinary Shares to the company (89,028 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Shannon James Samuel returned $6,616,501 worth of Ordinary Shares to the company (56,794 units at $116.50), closing all direct ownership in the company (SEC Form 4)
- Santini Gino returned $13,935,031 worth of Ordinary Shares to the company (119,614 units at $116.50), closing all direct ownership in the company (SEC Form 4)